DAIICHI SANKYO, INC.
第一三共 INC.
Alias
DAIICHI SANKYO, INC.(第一三共 INC.)
Alias
Daiichi Sankyo, Inc.
Alias
United States of America
Pharmaceutical development and manufacturing
Research and development of cardiovascular and oncology drugs
Clinical trials and regulatory affairs
Global distribution of pharmaceutical products
Oncology
Bone Health
Nephrology
Inflammatory Diseases
Biologic Products
Specialty Medicines
Clinical Research
Investigational Product Access
Collaborative Research
Cardiovascular
Diabetes
Gastrointestinal
Antibiotic
Drug discovery and development
Clinical research and trials
Ken Keller
1,200 people
20,000 people
Company name
Group
Parent
Subsidiary
Customer
Supplier
Alliance
Bank
Shareholder
Spectrum Pharmaceuticals
Group
Loading...
Loading the relationship graph...
1 entries
| Date | Description |
|---|
| 2022-05-27 |
At Daiichi Sankyo, we proudly observe Asian Pacific American Heritage Month (APAHM) in May. During this month, we recognize our own Asian heritage—Daiichi Sankyo is a global company based in Japan with more than 100 years of history in medical science. We also take this time to honor the achievements of Asians and Pacific Islanders to our society and our organization. We encourage open conversations and amplify the voices of our employees representing the Pan-Asian diaspora. We promote active steps toward inclusion and diversity, emphasizing cultural humility and understanding marginalized communities' histories and struggles. Fay Dunbar, Director of Inclusion & Diversity, stated that inclusion is key to unlocking the power of our people and that the company is committed to a diverse workplace reflecting the world and the patients served. |
2026-09-21 18:05 (Model: ggml-org/gpt-oss-20b )
